Neurocrine Biosciences (NBIX) Accounts Payables (2010 - 2026)

Neurocrine Biosciences' Accounts Payables history runs 17 years deep, the most recent figure standing at $773.0 million for Q1 2026.

• Quarterly Accounts Payables rose 62.67% year-over-year to $773.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $773.0 million (up 62.67% YoY) and the FY2025 annual result came in at $674.3 million, up 46.08% from the prior year.
• Accounts Payables was $773.0 million for Q1 2026 at Neurocrine Biosciences, up from $674.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $773.0 million in Q1 2026 and bottomed at $235.9 million in Q1 2022.
• A 5-year average of $439.6 million and a median of $417.2 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables surged 68.91% — and 2024, when it declined 21.93%.
• Neurocrine Biosciences' Accounts Payables stood at $347.6 million in 2022, then rose by 29.11% to $448.8 million in 2023, then increased by 2.85% to $461.6 million in 2024, then jumped by 46.08% to $674.3 million in 2025, then increased by 14.64% to $773.0 million in 2026.
• Business Quant data shows NBIX's Accounts Payables at $773.0 million in Q1 2026, $674.3 million in Q4 2025, and $584.3 million in Q3 2025.